Disease · EFO_0009364
non-allergic rhinitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. non-allergic rhinitis. Diseases, record EFO_0009364. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009364
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- non-allergic rhinitis
- Open Targets ID
- EFO_0009364
- Other names
- nonallergic rhinitis
- Highest stage of its drugs
- Approval, for 2 of its 9 drugs, from DailyMed
Source Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ASPIRIN | CHEMBL25 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| CAPSAICIN | CHEMBL294199 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SB-705498 | CHEMBL207433 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ESOMEPRAZOLE | CHEMBL1201320 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUTICASONE PROPIONATE | CHEMBL1473 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVOCETIRIZINE | CHEMBL1201191 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MOMETASONE FUROATE | CHEMBL1161 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXYMETAZOLINE | CHEMBL762 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Unknown | https://conductscience.org/library/genes/2908 | Drugs and targets |
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | 2 | Vanilloid receptor antagonist; Vanilloid receptor opener | Phase 3 | https://conductscience.org/library/genes/7442 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha agonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha agonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha agonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha agonist | Unknown | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha agonist | Unknown | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha agonist | Unknown | https://conductscience.org/library/genes/152 | Drugs and targets |
| ATP4A | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Unknown | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Unknown | https://conductscience.org/library/genes/496 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00745849 | Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial | Not applicable | 43 | 2019-06-11 | Vasomotor Rhinitis | ESOMEPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT01424514 | SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis | Phase 2 | 40 | 2018-01-29 | Rhinitis | SB-705498 | Its record names the disease | ClinicalTrials.gov |
| NCT05093478 | The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population | Phase 3 | 28 | 2024-12-20 | Non-allergic Rhinitis | CAPSAICIN | Its record names the disease | ClinicalTrials.gov |
| NCT05348148 | Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis | Not applicable | 450 | Allergic Rhinitis, Vasomotor Rhinitis | LEVOCETIRIZINE, MOMETASONE FUROATE, OXYMETAZOLINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01439308 | Intranasal SB-705498 in Non-allergic Rhinitis Patients | Phase 2 | 40 | Rhinitis | SB-705498 | Its record names the disease | ClinicalTrials.gov | |
| NCT02883439 | Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate | Not applicable | 0 | Bioavailability Study | FLUTICASONE PROPIONATE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SB-705498 12 mg vs Placebo: Number of Participants With Clinical Chemistry PCI Abnormalities of Albumin, Calcium, Glucose, Potassium, Sodium and Total Carbon Dioxide (CO2) at Any Time During Treatment | 1 of 39 | 0 of 38 | 77 | NCT01424514 | Trial comparisons |
| SB-705498 12 mg vs Placebo: deaths from any cause | 0 of 39 | 0 of 38 | 77 | NCT01424514 | Trial comparisons |
| SB-705498 12 mg vs Placebo: serious adverse events | 0 of 39 | 0 of 38 | 77 | NCT01424514 | Trial comparisons |
| Events Occurring While Subject Was on Esomeprazole vs Events Occurring While Subject Was on Placebo: deaths from any cause | 0 of 37 | 0 of 37 | 74 | NCT00745849 | Trial comparisons |
| Events Occurring While Subject Was on Esomeprazole vs Events Occurring While Subject Was on Placebo: serious adverse events | 0 of 37 | 0 of 37 | 74 | NCT00745849 | Trial comparisons |
Papers from its trials23
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0009364
GET https://conductscience.org/api/diseases/v1/EFO_0009364/papers?page=2